Aurobindo Pharma Limited reported its highest-ever quarterly revenue from operations of ₹10,263 crore for the July–September quarter (Q2 FY27), up 24% from ₹8,286 crore a year earlier, as its US, European and API businesses all grew by double digits. Consolidated net profit rose 32.5% to ₹1,124 crore, the Hyderabad-based drugmaker said on 4 November 2026.

The numbers stand out in a mixed results season for Indian generics makers, coming the same day Lupin reported a 22% fall in Q2 FY27 net profit despite higher sales.

Key takeaways

• Revenue from operations rose 23.9% year on year and 12.2% quarter on quarter to a record ₹10,263 crore.
• EBITDA before forex and other income climbed 28.5% to ₹2,156 crore, and the margin widened 75 basis points to 21%.
• US formulations revenue grew 25% to ₹4,555 crore, and Europe rose 27% to ₹3,161 crore.
• The company received final USFDA approval for 12 products and launched 10 products in the US, including its first new chemical entity.
• The board declared an interim dividend of ₹7 per share.

Aurobindo Pharma Q2 FY27 results at a glance

According to the company’s Q2 FY27 results press release, profit before tax (before its share of joint venture results) rose 32.7% to ₹1,691 crore. Net profit was up 8.9% from ₹1,032 crore in Q1 FY27, and basic and diluted earnings per share stood at ₹19.57.

Aurobindo generated free cash flow of USD 146 million in the quarter after strategic capital spending, and held a net cash position, including investments, of USD 189 million as of 30 September 2026. Research and development spending rose to ₹376 crore from ₹344 crore in the previous quarter.

How did each business perform?

• US formulations: Revenue rose 25.2% to ₹4,555 crore (USD 477 million), or 44% of total revenue, helped by acquisitions, base business growth and new launches.
• Europe formulations: Revenue rose 27.5% to ₹3,161 crore, or 18% in euro terms to EUR 288 million.
• Growth markets: Revenue grew 16.3% to ₹1,026 crore.
• Antiretrovirals (ARV): Revenue was broadly stable at ₹359 crore, with quarterly swings tied to tenders.
• Active pharmaceutical ingredients (API): Revenue rose 20.9% to ₹1,162 crore, with beta-lactam APIs up 24.8% to ₹858 crore.

USFDA approvals and US launches

Aurobindo received 12 final USFDA approvals in the quarter. They include a first-to-file generic of sacubitril and valsartan tablets for heart failure, bupropion extended-release tablets, cyclosporine capsules, brivaracetam oral solution and a beclomethasone inhalation aerosol. Eslicarbazepine acetate tablets moved from tentative to final approval.

As of 30 September 2026, the company had filed 900 ANDAs (abbreviated new drug applications) with the USFDA and received 747 final and 35 tentative approvals. Its 10 US launches in the quarter included a generic version of the Advair inhaler and ADQUEY, its first new chemical entity. Regulatory approvals remain a key growth driver across the sector, as seen in Lupin’s USFDA approval for generic amifampridine tablets.

What management said

“We are pleased to deliver a strong performance in Q2, reflecting the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio,” said K. Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma. He said growth came from organic momentum and the integration of acquisitions, and that the company would stay focused on financial discipline while expanding access to affordable medicines.

API makers have had a varied quarter. Aarti Drugs posted an 83% jump in Q2 FY27 profit, while Neuland Labs’ profit fell 47% as margins narrowed. Market data and reactions are tracked by InvestyWise and other outlets.

Frequently asked questions

What was Aurobindo Pharma’s revenue in Q2 FY27?

Aurobindo Pharma’s revenue from operations was ₹10,263 crore in Q2 FY27, its highest ever, up 24% from ₹8,286 crore in Q2 FY26.

How many USFDA approvals did Aurobindo receive in Q2 FY27?

The company received final USFDA approval for 12 products in the quarter and had 747 final approvals in total as of 30 September 2026.

Featured image: An aerial view of an Aurobindo Pharma manufacturing site. Photo: Aurobindo Pharma Limited

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!